MCCP
FTH

Mission Creek Capital Partners’s Faeth Therapeutics FTH Stock Holding History

Mission Creek Capital Partners’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,639
Closed -$345K – 260
2021
Q3 		$345K Buy
+1,639
New +$298K 0.06% 202

Other funds holding FTH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Mission Creek Capital Partners's FTH Position: Q4 2021 in Review

Mission Creek Capital Partners sold out of Faeth Therapeutics (FTH) in Q4 2021, closing a stake of 1,639 shares — an estimated $345K sold.

Mission Creek Capital Partners first reported a position in FTH in Q3 2021 and held it in 1 quarter. The position peaked at $345K in Q3 2021. 37 funds tracked by Wall St. Rank hold FTH as of Q4 2021.

  • Mission Creek Capital Partners reported no remaining Faeth Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Mission Creek Capital Partners sold 1,639 Faeth Therapeutics shares in Q4 2021, an estimated $345K.
  • Mission Creek Capital Partners first reported a position in Faeth Therapeutics in Q3 2021 and held it in 1 quarter.
  • Mission Creek Capital Partners's Faeth Therapeutics position peaked at $345K in Q3 2021.
  • 37 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q4 2021.

Based on Mission Creek Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.